ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
EU/EEA capacity for the surveillance of hepatitis B and C using molecular methods
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
Country mission Latvia: HIV, STI and hepatitis B and C
This report describes a country mission undertaken by ECDC in 2011 to Latvia, to address issues relating to HIV, STI and hepatitis B and C identified by the Latvian government.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA: Executive summary
Hepatitis B and C surveillance in Europe 2012
This is the second report on the enhanced surveillance of hepatitis B and C viral infections. It describes basic epidemiological features and trends of both diseases across countries in the EU/EEA for 2012.